期刊文献+

消旋-循环拆分法在手性药物合成中的应用

Application of Recycle Process of Resolution-racemization in Synthesis of Chiral Drugs
原文传递
导出
摘要 拆分是制备手性药物的经典方法。由于拆分剂价格低廉易得、方法成熟、操作简便、易于大规模生产等优势,拆分在制药工业生产中仍然具有一定的地位,但其主要缺点是有另一半不需要的对映异构体产生,造成很大浪费。在消旋化后进行循环拆分,是弥补这个缺点的直接、有效途径。该文主要按不同的消旋化机制[碳负(或正)离子机制和消除还原机制],综述了消旋-循环拆分法在手性药物合成中的应用。 The classic resolution of racemates is one of the choices for production of chiral compounds in large scale.Due to the advantages of inexpensive and readily available of resolution agents,mature methods,simple operation,and ease of large-scale production,resolution still plays a role in the pharmaceutical industry.However,its main disadvantage is that half of the products are unwanted enantiomers,resulting in significant waste.Recycle process of resolution-racemization is a direct and effective way to remedy this disadvantage.In this paper,the applications of recycle process of resolution-racemization in synthesis of chiral drugs are reviewed based on the different mechanisms of racemization(carbanion/carbocation mechanism and mechanism of elimination-reduction).
作者 吕训磊 林快乐 周伟澄 LYU Xunlei;LIN Kuaile;ZHOU Weicheng(Shanghai Key Lab.of Anti-infectives,State Key Lab.of New Drug and Pharmaceutical Process,Shanghai Institute of Pharmaceutical Industry,China State Institute of Pharmaceutical Industry,Shanghai 201203)
出处 《中国医药工业杂志》 CAS CSCD 北大核心 2023年第2期175-181,共7页 Chinese Journal of Pharmaceuticals
关键词 消旋化 循环拆分 碳负(或正)离子机制 消除还原机制 racemization recycle process of resolution carbanion/carbocation mechanism mechanism of elimination-reduction
  • 相关文献

参考文献8

二级参考文献66

  • 1宋丽晓.变应性咳嗽32例诊治体会[J].中国现代药物应用,2009,3(4):36-37. 被引量:2
  • 2臧健,王志军,吴怡祖.D-(-)-苯甘氨酸衍生物拆分DL-扁桃酸的研究[J].化学工业与工程技术,2005,26(1):5-8. 被引量:5
  • 3李外,古今,刘萍.琥珀酸索非那新投放美国市场用于膀胱过度活动症[J].国外医学(药学分册),2005,32(3):214-215. 被引量:5
  • 4Mealy N, Castaner J. YM-905 [J]. Drugs Future, 1999, 24(8): 871-874.
  • 5Naito R, Yonetoku Y, Okamoto Y, et al. Synthesis and antimuscarinic properties of quinuclidin-3-yl 1,2,3,4-tetrahydroisoquinoline-2-carboxylate derivatives as novel muscarinic receptor antagonists [J]. J Med Chem, 2005, 48 (21) : 6597-6606.
  • 6Wang S, Onaran MB, Seto CT, et al. Enantioselective synthesis of 1-aryltetrahydroisoquinolines [J]. Org Lett, 2010, 12 (12) : 2690-2693.
  • 7Ishii Y, Takaoka K, Inakoshi M, et al. Composition containing solifenacin succinate: EP, 1714965 [P]. 2006-10-25. (CA 2005, 143: 212051).
  • 8Sniegoski LT, Byrd GD, White E. Synthesis of 3-quinuclidinol-18 O, benzilic-d5 acid, and 3-quinuclidinyl- 180 benzilate-d5 [J]. J Labelled Compd Radiopharm, 1989, 27 (9) : 983-993.
  • 9Langlois M, Meyer C, Soulier JL. Synthesis of (R) and (S) - 3-aminoquinuclidine from 3-quinuclidinone and (S) and (R)-l-phenethylamine [J]. Synth Commun, 1992, 22(13): 1895-1911.
  • 10Han XY, Liu H, Liu CH, et al. Synthesis of the optical isomers of a new anticholinergic drug, penehyclidine hydrochloride (8018) [J]. Bioorg Med Chem Lett, 2005, 15(8) : 1979-1982.

共引文献39

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部